TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Conditions: Non-hodgkin Lymphoma Interventions: Biological: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T); Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Chinese PLA General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials